| Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors. | |
| | |
MedLine Citation:
|
PMID: 12911939 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Syndecan-1 (CD138) mediates myeloma cell adhesion, and loss of syndecan-1 from the cell surface may contribute to myeloma cell proliferation and dissemination and influence the prognosis in patients with multiple myeloma (MM). In order to test this hypothesis, we have evaluated syndecan-1 expression on the surface of malignant plasma cells and soluble forms of syndecan-1 in the serum of 25 newly diagnosed MM patients by flow cytometry and immunosorbent assay. Soluble syndecan-1 levels were significantly higher in MM as compared to controls (P<0.001). Cellular and soluble syndecan-1 was significantly inversely correlated (r=-0.89, P<0.001). The soluble syndecan-1 was significantly higher in non- responders to chemotherapy when compared to responders (P<0.01), and in non- survivors as compared to survivors (P<0.001). In contrast, cellular syndecan-1 expression was significantly lower in non- responders when compared to responders (P<0.01), and in non- survivors as compared to survivors (P<0.05). The levels of soluble syndecan-1 increased from stage I through stage II to stage III, whereas cellular syndecan-1 expression were decreased from high levels in stage III down to a low in stage I, with a statistically significant difference (P<0.01, P<0.05, respectively). There was a significant positive correlation between soluble syndecan-1 and plasma cell count (r=0.079, P<0.001), beta2 microglobulin (r=0.85, P<0.001), serum creatinine (r=0.84, P<0.001), C-reactive protein (r=0.082, P<0.001), alkaline phosphatase (r=0.58, P<0.05) and serum calcium (r=0.77, P<0.01) and a negative correlation with hemoglobin level (r=-0.78, P<0.01), platelets count (r=-0.82, P<0.01) and Albumin level (r=-0.64, P<0.01). Cox regression analysis using soluble syndecan-1 at mean-2SD of the controls could correctly classify patient outcome in 84.0%. The addition of beta2 microglobulin to soluble syndecan-1 increased the predictability of the patients' outcome to 96.7%. We conclude that soluble syndecan-1 levels are negatively correlated to the cellular form and that high levels of soluble syndecan-1 and lower expression of cellular syndecan-1 at diagnosis are negative prognostic factors. Assessment of soluble syndecan-1 and beta2 microglobulin at diagnosis is an independent prognostic system for MM. |
| | |
Authors:
|
Salah Aref; T Goda; M El-Sherbiny |
Related Documents
:
|
16368469 - Comparison of effects of pravastatin and hormone therapy on soluble p-selectin and plat... 10348699 - The biology of p-selectin glycoprotein ligand-1: its role as a selectin counterreceptor... 18753189 - Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral t... 1416849 - Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic... 12115179 - Elevated levels of platelet microparticles are associated with disease activity in rheu... 15533889 - Platelet-leukocyte aggregation induced by par agonists: regulation by nitric oxide and ... 17460299 - A potential role for pdgf-c in experimental and clinical proliferative vitreoretinopathy. 6233749 - The effect of platelet inhibitors on glycoprotein v hydrolysis by thrombin. 16368469 - Comparison of effects of pravastatin and hormone therapy on soluble p-selectin and plat... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Hematology (Amsterdam, Netherlands) Volume: 8 ISSN: 1024-5332 ISO Abbreviation: Hematology Publication Date: 2003 Aug |
Date Detail:
|
Created Date: 2003-08-12 Completed Date: 2004-01-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9708388 Medline TA: Hematology Country: England |
Other Details:
|
Languages: eng Pagination: 221-8 Citation Subset: IM |
Affiliation:
|
Hematology Unit, Clinical pathology Department, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt. salaharef@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Case-Control Studies Female Humans Male Membrane Glycoproteins / analysis*, blood, physiology Middle Aged Multiple Myeloma / chemistry, diagnosis*, etiology Plasma Cells / chemistry, pathology Prognosis Proteoglycans / analysis*, blood, physiology Regression Analysis Risk Factors Severity of Illness Index Solubility Survival Analysis Syndecan-1 Syndecans Treatment Outcome Tumor Markers, Biological / analysis, blood beta 2-Microglobulin / analysis |
| Chemical | |
Reg. No./Substance:
|
0/Membrane Glycoproteins; 0/Proteoglycans; 0/SDC1 protein, human; 0/Syndecan-1; 0/Syndecans; 0/Tumor Markers, Biological; 0/beta 2-Microglobulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Total registration of non-Hodgkin's lymphoma and Hodgkin's disease in Scotland: effect of deprivatio...
Next Document: Hodgkin's disease variant of Richter's syndrome: complete remission of the both malignancies after 1...